Journal
PEDIATRIC BLOOD & CANCER
Volume 69, Issue 4, Pages -Publisher
WILEY
DOI: 10.1002/pbc.29557
Keywords
brentuximab vedotin; Hodgkin lymphoma; immunotherapy; pediatric; refractory; relapse
Categories
Ask authors/readers for more resources
Combination therapy with brentuximab vedotin and bendamustine may be a suitable salvage therapy for children and young adults with Hodgkin's lymphoma, showing a high overall response rate and 3-year survival rate.
Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m(2) on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available